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Editorial
Tacrolimus is a macrolide with potent immuno-
suppressant properties. It was introduced in the late
1980s for use as an alternative to cyclosporine-A for
the prevention of graft rejection following solid organ
transplantation. The drug has a narrow therapeutic in-
dex [1], displays considerable variability in oral
pharmacokinetic profile between patients [2], and has
potential interaction with concomitant drugs including
immunosuppressants [3]. Because of these, regular
monitoring of drug levels is essential in the management
of transplant patients for optimal efficacy and minimal
toxicity [4,5].
After absorption, around 95% of tacrolimus binds
strongly to the erythrocytes and the remaining 5% is in
plasma [3]. Although the plasma level of the drug may
correlate better with clinical events, whole blood
monitoring is usually preferred because it is technically
less difficult [6]. Most transplant centers monitor whole-
blood trough levels of the drug [4,7]. Some centers
advocate  monitor ing of  the area under  the
concentration-time curve (AUC) for a better estimate
of systemic drug exposure despite patient inconvenience
and higher laboratory costs. In this regard, a number of
limited blood sampling strategies to estimate the AUC
of tacrolimus have been proposed [8]. However, it
should be noted that the abbreviated equation may not
be reliable if the exact sampling times are not followed
[9].
Monitoring of drug levels is complicated by
specificity of the analytical methods. The interpretation
of a tacrolimus level may be misleading without
knowing what kind of assay is being used. Most of the
studies correlate the clinical outcomes with tacrolimus
level using immunoassay-based methods. It should be
realized that these methods measure both the parent
drug and several of its metabolites [1,7]. In this issue
of the Hong Kong Journal of Nephrology, Chan et al
addressed this issue by comparing the whole blood
tacrolimus level as measured by the nonspecific
immunoassay method with that measured by the highly
specific high performance liquid chromatography
tandem mass spectrometry (HPLC-MS/MS) method
[10]. The authors found that the immunoassay over-
estimated the drug level by a median value of 5.04%.
The degree of overestimation is much smaller than that
reported by other studies [5], and the authors postulated
that it might relate to a difference in the timing of blood
sampling [10]. This postulation is supported by the
finding of Gonschior et al who demonstrated that the
difference between the drug levels measured by the two
methods varied considerably over time after the dose
Therapeutic Drug Monitoring of Tacrolimus
of tacrolimus in liver graft recipients [11]. Other
reported factors that may affect the tacrolimus
metabolite patterns and, hence, exaggerate the differ-
ences between immunoassay methods and HPLC-MS/
MS methods include impaired liver function [1,12], low
packed cell volume and low plasma albumin level [13].
All these data strongly suggest that a specific method
like HPLC-MS/MS should be the candidate reference
method to monitor tacrolimus levels to reduce the risk
of under-immunosuppression.
To complicate the issue more, it should be noted
that some, but not all, of the immunoassay-recognized
tacrolimus metabolites may have immunosuppressive
properties [7,14]. This also makes the immunoassay
results non-predictive of immunosuppressant activity.
Based on an animal model, the relative immuno-
suppressant activity of the metabolites M-I, M-II, M-
IV, M-VI, and M-VIII was 6.4%, 100%, 3.5%, 1.3%,
and 0.7% of that of the tacrolimus parent drug,
respectively [14]. Of these, M-II and M-VI have been
found to be cross-reacted by the immunoassay (109%
and 8.8%, respectively, compared with the parent drug).
Further study may be warranted to investigate the
possible clinical benefit of considering the immuno-
suppressive effect of tacrolimus metabolites, for
instance M-II, a metabolite with the highest immuno-
suppressant property, as well as the parent drug in
therapeutic drug monitoring. In addition, it would be
prudent to review the therapeutic target ranges of
tacrolimus and to test the validity of the abbreviated
tacrolimus AUC equation when the specific HPLC-MS/
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